Metabolic Disorders Flashcards

1
Q

PKU

A
  • MOST COMMON amino aciopathy (1/10,000-15,000)
  • AR mutations in PAH
  • untreated: ID, seizures, musty odor, psych
  • inc. phenylalanine, dec. tyrosine
  • treated: generally unaffected
  • dietary protein restriction
  • Kuvan works for some
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Tyrosinemia type I

A
  • amino aciopathy
  • AR mutations in FAH
  • more common in Quebec (1/16,000)
  • untreated: liver failure in infancy, kidney dysfxn, growth failure, rickets, neuro crises, death <10y, rotton eggs odor
  • increased phenylalanine and tyrosine in plasma, increased succinylacetone in urine
    treated: inc. risk hepatocellular carcinoma, corneal cysts, normal growth, increased liver fxn
  • drug treatment NTBC, dietary protein restriction, manage liver disease
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Homocytinuria

A
  • amino aciopathy
  • AR mutations in CBS
  • more common in Qatar (1/1,800)
  • untreated: ID, marfanoid, ectopia lentis (down), thromboembolism, neuro sequelae
  • increased homocystine and methionine
  • treated: inc. risk for thromboembolism, risk of ectopia lentic, normal growth and intelligence
  • supplement with B6, folate, B12, dietary protein restriction, avoid OCPs
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

MSUD

A
  • amino aciopathy
  • AR mutations in BCKDHA (45%), BCKDHB (35%), DBT (20%)
  • more common in Mennonites
  • newborn metabolic crisis: irritability, feeding and resp issues, opisthotonas
  • reduced IQ, movement disorders, risk of depression, ADHD, and anxiety
  • increased BCAAs (leucine, isoleucine, valine)
  • dietary protein restriction (most aggressive when sick)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Amino acidopathies presentation

A
  • chronic and progressive
  • usually no neonatal crisis (except MSUD)
  • all AR
  • symptoms develop slowly
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Urea cycle defects

A
Neonatal presentation:
- increased ammonia, encephalopathy, resp. alkalosis:
- seizure, coma, death
- resembles sepsis but normal glucose
- onset 24-72hrs of life
Childhood and adult presentation
-  infections, neuro involvement, psych issues
- PREVENT CATABOLISM
- SUPPLEMENT WITH ARGININE (unless ARG)
LIVER TRANSPLANT = CURE
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

CPS deficiency

A
  • urea cycle defect
  • AR mutations in CPS1
  • plasma AAs: low citrulline and arginine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

OTC deficiency

A
  • MOST COMMON urea cycle defect
  • XL mutations in OTC
  • plasma AAs: low citrulline and arginine
  • high urinary orotic acid
  • 10-15% CARRIER females symptomatic
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

ASS deficiency/Citrullinemia

A
  • urea cycle defect
  • AR mutations in ASS1
  • super inc. citrulline, dec. arginine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

ASL deficiency

A
  • urea cycle defect
  • AR mutations in ASL
  • inc. citrulline and arginosuccinate, dec. arginine
  • variable
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

ARG deficiency

A
  • urea cycle defect
  • AR mutations in ARG1
  • onset 1-3y: progressive spasticity, psychomotor retardation, feeding issues, DD, seizures
  • increased arginine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Organic Acidurias

A
  • high risk of decompensation prior to NBS results
  • prevent catabolism!
  • acute presentation: toxic encephalopathy, dec. feeding, poor tone, seizures, irritability, lethargy -> coma
  • all AR
  • treat with carnitine supplementation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Propionic acidemia

A
  • organic aciduria
  • AR mutations in PCCA, PCCB
  • cannot metabolize: isoleucine, valine, threonine, methionine
  • neonatal fast breathing
  • cardiomyopathy
  • pancreatitis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Glutaric Acidemia

A
  • MOST COMMON organic aciduria (1/30-40,000)
  • AR: GCDH
  • up to 1/300 Amish
  • metabolic crisis after 2 months
  • severe movement disorder: spasticity/dystonia (from glutaric acidemia)
  • macrocephaly
  • treat: low lysine diet
  • 30-40% have neuro impariment w/ treatment
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Methlymalonic aciduria

A
  • organic aciduria
  • AR: MUT (genotype/phenotype…22% have limited activity)
  • looks like PA in severe genotype
  • very high MMA
  • treatment: DPR, B12 injections, prophylactic antiboitics
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Isovaleric Aciduria

A
  • organic aciduria
  • AR: IVD
  • similar to PA and MMA neonatal crisis, BUT fewer longterm complications
  • “sweaty feet odor”
  • treatment: low leucine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Metabolic conditions w/ psychiatric findings

A

PKU, Galactosima, MCADD, ASA, Citrullinemia (ASD), homocystinuria

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Fatty Acid Oxidation Disorders

A
  • causes sudden infant death
  • avoid fasting!
  • low fat diet w/ fatty acid supplementation
  • cornstarch
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

SCAD

A
  • not a disorder…in vast majority

-

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

MCADD

A
  • most common fatty acid oxidation disorder
  • AR: ACADM
  • NBS: ^C6-C10
  • presentation 3-24 months (when feeds decrease at night)
  • vomiting, seizure etc etc
  • hypoketotic hypoglycemia
  • no impact on congnition if caught early
  • acute liver disease
21
Q

LCHAD

A
  • FAOD
  • AR: HADHA
  • NBS: ^C14-C18
  • female carriers at risk for HELLP during pregnancy (treatment=delivery)
  • cardiomyopathy, liver disease, hypotonia, neuropathy, retinopathy
22
Q

VLCAD

A
  • FAOD
  • AR: ACADVL
  • NBS: ^C14
  • cardiac issues, hypotonia, hepatomegaly, intermittent hypoglycemia
23
Q

CPTII

A
  • FAOD
  • AR: CPT2
  • lethal neonatal form: liver failure, CM, death in days/mos
  • Severe infantile form: liver failure, CM, onset in 1st year, sudden death common
  • Myopathic form: most common, variable AOO, myalgia attacks only
24
Q

Sphingolipidoses

A
  • 3 classes 1) cerebrosides 2) sphingomyelins 3) gangliosides
  • Niemann-Pick
  • Gaucher
  • Fabry
  • Tay Sachs (GM2)
  • Krabbe
  • Metachromatic Leukodystrophy
25
Q

Niemann-Pick

A
  • LSD/sphingolipidosis
  • AR: SMPD1
  • Type A: neuropathic, HSM, FTT, regression at 1yr, 100% have cherry red spot, respritory failure, early childhood death
  • Type B: non-neuropathic, similar but later onset, 1/3 neuro impairment and cherry red spot, delayed bone age, short stature
26
Q

Gaucher

A
  • MOST COMMON LSD/sphingolipidosis
  • AR: GBA
  • Type 1: least severe and most common, ERT (cannot cross BBB), excellent prognosis
  • Type 2: most severe, 2-4 yr lifespan
  • Type 3: intermediate, chronic neuro disease
  • Features: bone disease, HSM, anemia, thrombocytopenia, lung disease, decreased platelets
27
Q

Fabry

A
  • LSD/sphingolipidosis
  • XL: GLA
  • childhood/adolescent onset
  • Features: stroke, renal failure, CM, corneal opacities, GI issues, hypohydrosis/anhhydrosis
  • Males=enzyme testing, females=molecular testing
  • a lot of depression and anxiety in Fabry families
  • untreated= ESRD/CVD by 3rd to 5th decade
  • ERT= lowers substrate, but not proven to extend life
28
Q

GM2/ Tay Sachs

A
  • LSD/sphingolipidosis (gangliosidosis)
  • AR: HEXA
  • b-hexosaminidase A
  • onset 6 months: exaggerated startle response, loss of milestones, macular cherry red spot, spacticity, trouble swallowing, seizures,
  • death from asphyxiation 2-4yrs.
  • palliative
  • adult onset=ataxia + psychosis
29
Q

Krabbe

A
  • LSD/sphingolipidosis
  • AR: GALC b-galactocerebrocidase
  • usually 30 kb deletion
  • leukodystrophy, demylenating CNS+PNS
  • progressive: DD, regression, irritability, hypertonia, peripheral neuropathy, white matter disease, ^CSF protein concentration
30
Q

Mucopolysacharidoses

A
  • lack of lysosomal enzymes that break down glycosaminoglycans (aka mucopolysaccharides)
  • bone marrow
31
Q

Hurler

A
  • MPS I
  • AR: IUDA
  • severe ID/DD, corneal clouding, coarse facies, umbilical hernia at birth, hydrocephalus, hepatosplenomegaly, dysostosis multiplex, heart valve abnormalities, hearing loss, gibbus deformity, chronic resp. infections
  • ERT available, death in 8-10y without
32
Q

Hunter

A
  • MPS II
  • XLR: IDS
  • onset 2-4y
  • NO CORNEAL CLOUDING, HSM, communicating hydrocephalus, camptodactyly, joint contractures, “pebbly” skin, recurrent ear infections, hirsuitism, gait abnormality, cardiac problems, respiratory infections
33
Q

Scheie

A
  • MPS I-S
  • AR: IUDA
  • onset after age 5
  • no psychomotor impairment, normal height, normal lifespan, normal intelligence
  • retinal degeneration, severe progressive skeletal disease, deafness, carpel tunnel syndrome
  • ERT available, more successful when no neuro involvement
34
Q

Sanfilippo

A
  • MPS III (MOST COMMON MPS)
  • AR: 4 genes (clinically same)
  • CNS degeneration 2-6y, profound ID by 6-10y, severe sleep disturbances, NO corneal clouding, typically normal stature, seizures (late stage)
  • no therapy, death in adolescence - early 20s
35
Q

Morquio

A
  • MPS IV
  • AR: 2 genes (clinically same)
  • severe skeletal involvement: shortening of trunk, kyphosis, C spine instability (spinal cord compression), pectus carinatum, dental abnormalities
  • normal intelligence
  • mitral valve insufficiency
  • mild corneal clouding and HSM
  • ERT for type A, survival to adulthood
36
Q

Maroteaux-Lamy

A
  • MPS VI
  • onset of growth retardation at 2-3y
  • resembles Hurler, but normal intelligence
  • shortened lifespan
  • cardiovascular disease
  • progressive pulm HTN
  • ERT available
37
Q

Sly

A
  • MPS VII
  • AR
  • slydrops fetalis in severe form
  • Hurler-like in moderate form: HSM, ID, dysostosis multiplex, coarse facies, short stature
  • No ERT, death in teens
38
Q

Alpha-mannosidosis

A
  • oligosaccharidosis
  • AR: MAN2B1
  • clinically resembles an MPS but MPSs in urine are normal because enzymes never make it to lysosomes
39
Q

Glycogen storage disorders

A
  • increased glycogen in tissues
  • LIVER: Von Gierke (GSD I), Cori (GSD III), Anderson (GSD IV)
  • LIVER & MUSCLE: Phosphorylase kinase deficiency (GSD IX)
  • MUSCLE: Pompe (IIa), McArdle (V)
40
Q

Von Gierke

A
  • GSD I
  • MOST COMMON GSD
  • AR: G6PC, SLC37A4
  • primarily affects liver
  • hepatomegaly, kidney failure, thrombocyte dsfxn
  • avoid fasting, supplement w/ cornstarch
41
Q

Pompe

A
  • GSD IIa
  • AR: GAA
  • more common in AA
  • primarily affects heart and muscle (myopathy and CM)
  • infantile form = death by 2
  • juvenile form = myopathy
  • adult form = similar to MD
  • ERT available
42
Q

McArdle

A
  • GSD V
  • MOST COMMON MUSCLE GSD
  • AR: PYGM
  • affects muscles: exercise intol., inc. CK
  • “warm up phenomenon”
43
Q

Galactosemia

A
  • AR: GALT
  • brain damage, cataracts, jaundice, hepatomegaly, sepsis
  • treat: lactose and galactose restriction
  • diet independent long term complications: DD, ataxia, anxiety, depression, POF
44
Q

Hereditary fructose intolerance

A
  • AR: ALDOB
  • appears when fruits/juice enter diet
  • lethargy, jaundice, seizure, coma
  • treat: no fructose, sorbitol, sucrose
45
Q

Lesch-Nyhan

A
  • XL: HRPT1
  • hyperuricemia –> gout, urea crystals
  • dystonia, chorea, self-injury
  • disorder of purine metabolism
46
Q

Batten disease

A
  • AR: CLN#
  • epilepsy, movement disorder, cognitive decline
  • terminal
  • regression
47
Q

Metabolic Psych Stuff

A
  • PKU: learning difficulties
  • Galactosemia: social anxiety
  • MCAD: withdrawn, lang. delays
  • Citrullinemia: delayed motor skills
48
Q

ERT available

A
  • MPS I (Hurler)
  • MPS II (Hunter)
  • MPS IVA (Morquio A)
  • MPS VI (Maroteaux-Lamy)
  • Gaucher
  • Fabry